Bispecific therapy – management of long-term adverse events in the community setting

Video content above is prompted by the following:

What are challenges that you foresee for management of longer-term AEs in the community setting and how can they be addressed? What is the impact of AEs on treatment completion rates?

Hypogammaglobulinemia (Baird JH et al. Blood Adv. 2021; 5(1):143-155. )

Cytopenias (Jain T et al. Blood. 2023;141(20):2460-2469.)

Infection (Hill JA et al. Blood. 2020; 136(8):925-935.)